Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 12/20 | 0.53 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | HTR7 | P34969 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.46 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.46 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.46 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.46 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.46 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.46 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6540449 | 0.99 | TACR1 (0.53) | TACR1GNAI3CYP2D6USP2SLC6A2 | |
| Hydrochloric Acid SCHEMBL6539724 | 0.99 | TACR1 (0.53) | TACR1GNAI3CYP2D6USP2SLC6A2 | |
| Hydrochloric Acid SCHEMBL6540599 | 0.86 | TACR1 (0.54) | TACR1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL6540235 | 0.83 | TACR1 (0.51) | TACR1SLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL6541279 | 0.82 | TACR1 (0.69) | TACR1CYP2D6SLC6A3KCNH2TMEM97 | |
| SCHEMBL6335455 | 0.79 | TACR1 (0.55) | TACR1CYP2D6 | |
| SCHEMBL6335458 | 0.79 | TACR1 (0.55) | TACR1CYP2D6 | |
| SCHEMBL6960206 | 0.79 | GNAI3 (0.53) | TACR1GNAI3CYP2D6USP2MEN1 | |
| Hydrochloric Acid SCHEMBL6540731 | 0.79 | TACR1 (0.51) | TACR1KMT2A | |
| Hydrochloric Acid SCHEMBL6541504 | 0.78 | TACR1 (0.56) | TACR1CYP2D6MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040220403-A1 | 1-(2-Methoxybenzyl)-3-benzhydrylpiperazines as tachykinin anatgonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-11-04 | — | — | US | disclosed |
| EP-1368343-A1 | 1-(2-METHOXYBENZYL)-3-BENZHYDRYLPIPERAZINES AS TACHYKININ ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-12-10 | — | — | EP | disclosed |
| EP-1368343-A1 | 1-(2-METHOXYBENZYL)-3-BENZHYDRYLPIPERAZINES AS TACHYKININ ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-12-10 | — | — | EP | disclosed |
| WO-2002055518-A1 | 1-(2-METHOXYBENZYL)-3-BENZHYDRYLPIPERAZINES AS TACHYKININ ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-07-18 | — | — | WO | disclosed |
| WO-2002055518-A1 | 1-(2-METHOXYBENZYL)-3-BENZHYDRYLPIPERAZINES AS TACHYKININ ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220403-A1 | 1-(2-Methoxybenzyl)-3-benzhydrylpiperazines as tachykinin anatgonists | BDKRB1, BDKRB2, TACR1 | TACR1 3/4885GNAI3 885/4885CYP2D6 1939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.